Journal of Biosciences and Medicines, Год журнала: 2024, Номер 12(12), С. 424 - 437
Опубликована: Янв. 1, 2024
Язык: Английский
Redox Biology, Год журнала: 2024, Номер 75, С. 103270 - 103270
Опубликована: Июль 18, 2024
Ferroptosis, driven by iron-dependent phospholipid peroxidation, is emerging as an intrinsic cancer defense mechanism. However, the regulatory networks involved in ferroptosis remain largely unknown. Here, we found that serine beta-lactamase-like protein (LACTB) inhibits liver progression regulating ferroptosis. LACTB downregulated cancer, and ectopic expression of markedly cell viability, colony formation, tumour growth. knockout exerts opposite effects. Further investigation revealed blocks HSPA8 transcription a p53-dependent manner, resulting elevation NCOA4-mediated ferritinophagy inhibition SLC7A11/GSH/GPX4 signalling, thereby triggering suppressing progression. Liver cells with endogenous mutation p53 binding site promoter exhibited increased resistance to inducers, ferroptosis-promoting effect was significantly weakened these mutant cells. Importantly, identified downstream target lenvatinib, adeno-associated virus-mediated overexpression knockdown notably enhance attenuate anti-tumour efficacy lenvatinib vivo, respectively. Taken together, our study reveals novel action provides potential therapeutic strategies for enhancing cancer.
Язык: Английский
Процитировано
6
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Фев. 12, 2025
Background Hepatocellular carcinoma (HCC), a prevalent malignancy, is often diagnosed at advanced stages. Recent advances have integrated immunotherapy with targeted therapy, significantly improving treatment outcomes. This study provides bibliometric overview of these therapeutic combinations, evaluating their development and impact. Methods A rigorous selection process was applied to relevant literature from Web Science, followed by in-depth analyses— including timeline visualization, burst detection, co-occurrence analysis—using CiteSpace VOSviewer. approach offered insights into the contributions countries, institutions, authors, journals, references, key terms within field. Results total 506 studies published between 2014 2023 were included, all articles in English. Mainland China dominated publication output, contributing 40% (N = 202), significant United States Japan. Kindai University led institutional contributions, accounting for 7.9% 40). The authors Kudo Masatoshi Hatanaka Takeshi most prolific, each nine publications. journal Cancers emerged as top publisher, 48 an Impact Factor 5.2 2022. co-citation network analysis traced evolution therapy combinations HCC treatment. Early research primarily focused on angiogenesis, dendritic cells, expression markers, while recent trends shifted towards phase III trials, adverse reactions, checkpoint inhibitors, underscoring field’s dynamic progression. Conclusion Future will expand pathological mechanisms underlying therapies novel interventions combination strategies. Addressing events discontinuation remain central advancing clinical applications.
Язык: Английский
Процитировано
0
Journal of Hepatocellular Carcinoma, Год журнала: 2025, Номер Volume 12, С. 445 - 458
Опубликована: Фев. 28, 2025
Previous LAUNCH trial revealed the promising effectiveness of transarterial chemoembolization (TACE) combined with lenvatinib for advanced hepatocellular carcinoma (HCC). However, most intermediate-stage HCC exceeds up-to-seven criteria, limiting their potential TACE benefits. Hepatic arterial infusion chemotherapy (HAIC) was widely endorsed delivering substantial survival benefits high tumor burden HCC, outperforming TACE. Accordingly, we undertook this study to evaluate efficacy and safety HAIC plus beyond criteria. From June 2017 November 2021, clinical data patients criteria received or alone from four medical centers in China were retrospectively collected. Propensity score matching (PSM) inverse probability weighting (IPTW) applied balance baseline differences. The Kaplan-Meier method utilized analysis. Cox regression-based multivariate analysis used identify survival-related risk factors. We compare response incidence adverse reactions between groups. A total 294 (the TACEHL group, n = 127) monotherapy 167) finally enrolled. Following propensity matching, median OS PFS group 34.6 months 15.7 months, respectively, significantly higher than 6.9 observed group. In response, ORR 71.4% 30.8% (P < 0.001), DCR 92.3% 75.8% 0.005). 3-4 grade comparable For integration therapy demonstrated enhancements prognosis, which is a treatment regimen.
Язык: Английский
Процитировано
0
International Journal of Nanomedicine, Год журнала: 2025, Номер Volume 20, С. 2623 - 2643
Опубликована: Март 1, 2025
In recent years, nanobiotechnology, widely used in hepatoma, holds great promise for improving targeted hepatocarcinoma therapy. On account of the unique properties low toxicity, good tolerance, biocompatibility, and biodegradability new nanomaterials, a drug delivery system (TDDS) has been constructed, which can boost therapeutic effect hepatoma-targeted drugs, reduce minimize off target reactions by enhancing permeability retention (EPR) active targeting, thus existing liver cancer therapy strategies. Different nanoparticles have their own advantages disadvantages. They be loaded with multiple drugs on same nanoparticle also surface modified each other to achieve synergistic anti-tumor effects. This essay provides comprehensive overview current status hepatocarcinoma, nanoparticles' structure, disadvantages nanoparticle, application progress cancer. We hope provide basis future clinical hepatoma using nanotechnology.
Язык: Английский
Процитировано
0
World Journal of Clinical Oncology, Год журнала: 2025, Номер 16(4)
Опубликована: Март 26, 2025
BACKGROUND Early symptoms of hepatocellular carcinoma (HCC) are not obvious, and more than 70% which does receive radical hepatectomy, when first diagnosed. In recent years, molecular-targeted drugs combined with immunotherapy other therapeutic methods have provided new treatment options for middle advanced HCC (aHCC). Predicting the effect targeted has become a hot topic in current research. AIM To explore relationship between nodule enhancement hepatobiliary phase efficacy aHCC. METHODS Data from 56 patients aHCC magnetic resonance imaging gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid were retrospectively collected. Signal intensity intrahepatic nodules was measured, relative ratio (RER) calculated. Progression-free survival (PFS) high low reinforcement compared. The model validated using receiver operating characteristic curves. Univariate multivariate logistic regression Kaplan-Meier analysis performed to factors influencing immunization PFS. RESULTS analyses revealed that RER, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte prognostic nutritional index significantly associated tyrosine kinase inhibitors (P < 0.05). area under curve RER predicting anti-programmed death 1 antibody 0.876 (95% confidence interval: 0.781-0.971, P 0.05), optimal cutoff value 0.904, diagnostic sensitivity 87.5%, specificity 79.2%. showed 5, 300, 45, 0.9 improved CONCLUSION AHCC stage correlated Imaging information immunological indicators had predictive
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(7), С. 3143 - 3143
Опубликована: Март 28, 2025
It is estimated that between 80 and 90% of mortality in cancer patients directly or indirectly related to drug resistance. Consequently, overcoming resistance represents a significant challenge the treatment cancer. Integrins are transmembrane adhesion molecules facilitate linkage extracellular matrix (ECM) cytoskeleton, thereby enabling activation various cellular signaling pathways. highly expressed cancers contribute progression through invasion metastasis. In addition, recent studies have revealed integrins play pivotal role development This review will first provide an overview integrin function classification. then discusses advances understanding how cancer, with focus on ECM, transporters, epithelial-to-mesenchymal transition (EMT), stemness, PD-L1, glycosylation. Finally, potential applications as targets for therapeutic agents against drug-resistant also summarized.
Язык: Английский
Процитировано
0
Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер unknown, С. 104735 - 104735
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
BMC Gastroenterology, Год журнала: 2025, Номер 25(1)
Опубликована: Апрель 23, 2025
Язык: Английский
Процитировано
0
Cellular Oncology, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 25, 2024
Lenvatinib is a potent first-line therapy for patients with hepatocellular carcinoma (HCC), but it also increased the number of neutrophils in HCC tumor microenvironment. CitH3, MPO-DNA, elastase and MPO activity were measured assessing neutrophil extracellular traps (NETs) vivo vitro. Cell cuproptosis was assessed by measurement copper content, FDX1, pyruvate. The functions lenvatinib, DNase I, interleukin 33 (IL33) neutralizing antibody GPX4 growth explored mice. induced NETs microenvironment via cells, not through direct stimulation neutrophils. In addition, NET clearance I improves efficacy lenvatinib mouse models. Mechanistically, promoted expression secretion IL33 cells that triggered formation. Moreover, knockdown Hepa1-6 improved Hepa1-6-bearing model mice reduced formation Subsequently, production increasing NDUFA4L2 cells. Furthermore, we found protein PADI4 Akt/mTOR signaling pathway. Rapamycin inhibition mTOR Consistently, selective PAD4 inhibitor GSK484 hydrochloride (GSK484) response to therapy. Importantly, contribute resistance inhibiting cuproptosis, apoptosis, pyroptosis, or ferroptosis Treatment reversed inhibitory effects on sensitized lenvatinib. Our study revealed lenvatinib-induced inhibited suggesting targeting IL33/PADI4/NET axis represents promising therapeutic strategy ameliorating HCC.
Язык: Английский
Процитировано
2
Experimental and Therapeutic Medicine, Год журнала: 2024, Номер 28(3)
Опубликована: Июль 5, 2024
Hepatocellular carcinoma (HCC) is one of the most aggressive types cancer. Although it has a high mortality rate, there currently no effective treatment for HCC. Lenvatinib traditionally been used as first‑line advanced HCC (aHCC); however, resistance to this therapy common. It can be difficult select second‑line drugs overcome lenvatinib when treating aHCC. For patients with aHCC, poor efficacy result in missing optimal window and lead an irreversible situation. Lenalidomide begun treat HCC; best our knowledge, its lenvatinib‑resistant remains reported on literature. The present case report, describes first literature patient aHCC who achieved partial response after regimen was switched lenalidomide. report provides promising novel route
Язык: Английский
Процитировано
1